 Connection
Christina Aquilante to Pharmacogenetics
This is a "connection" page, showing publications Christina Aquilante has written about Pharmacogenetics.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
6.427 |
|
|
|
-
Aquilante CL, Trinkley KE, Lee YM, Crooks KR, Hearst EC, Heckman SM, Hess KW, Kudron EL, Martin JL, Swartz CT, Kao DP. Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program. Am J Health Syst Pharm. 2024 Jun 11; 81(12):555-562.
Score: 0.854
-
Martin JL, Lee YM, Corbin LW, Colson R, Aquilante CL. Patients' perspectives of a pharmacist-provided clinical pharmacogenomics service. Pharmacogenomics. 2022 06; 23(8):463-474.
Score: 0.736
-
Nagy M, Lynch M, Kamal S, Mohamed S, Hadad A, Abouelnaga S, Aquilante CL. Assessment of healthcare professionals'?knowledge, attitudes, and perceived challenges of clinical pharmacogenetic testing in Egypt. Per Med. 2020 07 01; 17(4):251-260.
Score: 0.649
-
Aquilante CL, Kao DP, Trinkley KE, Lin CT, Crooks KR, Hearst EC, Hess SJ, Kudron EL, Lee YM, Liko I, Lowery J, Mathias RA, Monte AA, Rafaels N, Rioth MJ, Roberts ER, Taylor MR, Williamson C, Barnes KC. Clinical implementation of pharmacogenomics via a health system-wide research biobank: the University of Colorado experience. Pharmacogenomics. 2020 04; 21(6):375-386.
Score: 0.633
-
Deininger KM, Tran JN, Tsunoda SM, Young GK, Lee YM, Anderson HD, Page Ii RL, Hirsch JD, Aquilante CL. Stakeholder perspectives of the clinical utility of pharmacogenomic testing in solid organ transplantation. Pharmacogenomics. 2019 12; 20(18):1291-1302.
Score: 0.623
-
Aquilante CL. Pharmacogenetics of thiazolidinedione therapy. Pharmacogenomics. 2007 Aug; 8(8):917-31.
Score: 0.265
-
Aquilante CL, Zineh I, Beitelshees AL, Langaee TY. Common laboratory methods in pharmacogenomics studies. Am J Health Syst Pharm. 2006 Nov 01; 63(21):2101-10.
Score: 0.252
-
Aquilante CL, Lobmeyer MT, Langaee TY, Johnson JA. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy. 2004 Jun; 24(6):720-6.
Score: 0.213
-
Tuteja S, Salloum RG, Elchynski AL, Smith DM, Rowe E, Blake KV, Limdi NA, Aquilante CL, Bates J, Beitelshees AL, Cipriani A, Duong BQ, Empey PE, Formea CM, Hicks JK, Mroz P, Oslin D, Pasternak AL, Petry N, Ramsey LB, Schlichte A, Swain SM, Ward KM, Wiisanen K, Skaar TC, Van Driest SL, Cavallari LH, Bishop JR. Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. Clin Transl Sci. 2022 02; 15(2):371-383.
Score: 0.177
-
Duarte JD, Dalton R, Elchynski AL, Smith DM, Cicali EJ, Lee JC, Duong BQ, Petry NJ, Aquilante CL, Beitelshees AL, Empey PE, Johnson JA, Obeng AO, Pasternak AL, Pratt VM, Ramsey LB, Tuteja S, Van Driest SL, Wiisanen K, Hicks JK, Cavallari LH. Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genet Med. 2021 12; 23(12):2335-2341.
Score: 0.175
-
Lazorwitz A, Aquilante CL, Shortt JA, Sheeder J, Teal S, Gignoux CR. Applicability of ancestral genotyping in pharmacogenomic research with hormonal contraception. Clin Transl Sci. 2021 09; 14(5):1713-1718.
Score: 0.172
-
Liko I, Lee YM, Stutzman DL, Blackmer AB, Deininger KM, Reynolds AM, Aquilante CL. Providers'?perspectives on the clinical utility of pharmacogenomic testing in pediatric patients. Pharmacogenomics. 2021 04; 22(5):263-274.
Score: 0.170
-
Hicks JK, El Rouby N, Ong HH, Schildcrout JS, Ramsey LB, Shi Y, Anne Tang L, Aquilante CL, Beitelshees AL, Blake KV, Cimino JJ, Davis BH, Empey PE, Kao DP, Lemkin DL, Limdi NA, P Lipori G, Rosenman MB, Skaar TC, Teal E, Tuteja S, Wiley LK, Williams H, Winterstein AG, Van Driest SL, Cavallari LH, Peterson JF. Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems. Clin Pharmacol Ther. 2021 07; 110(1):179-188.
Score: 0.170
-
Deininger KM, Tsunoda SM, Hirsch JD, Anderson H, Lee YM, McIlvennan CK, Page RL, Tran JN, Aquilante CL. National survey of physicians' perspectives on pharmacogenetic testing in solid organ transplantation. Clin Transplant. 2020 10; 34(10):e14037.
Score: 0.163
-
Anderson HD, Crooks KR, Kao DP, Aquilante CL. The landscape of pharmacogenetic testing in a US managed care population. Genet Med. 2020 07; 22(7):1247-1253.
Score: 0.160
-
Deininger KM, Page RL, Lee YM, Kauffman YS, Johnson SG, Oreschak K, Aquilante CL. Non-interventional cardiologists' perspectives on the role of pharmacogenomic testing in cardiovascular medicine. Per Med. 2019 03; 16(2):123-132.
Score: 0.146
-
Weitzel KW, Aquilante CL, Johnson S, Kisor DF, Empey PE. Educational strategies to enable expansion of pharmacogenomics-based care. Am J Health Syst Pharm. 2016 Dec 01; 73(23):1986-1998.
Score: 0.127
-
Castillo-Mancilla JR, Aquilante CL, Wempe MF, Smeaton LM, Firnhaber C, LaRosa AM, Kumarasamy N, Andrade A, Baheti G, Fletcher CV, Campbell TB, Haas DW, MaWhinney S, Anderson PL. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). J Antimicrob Chemother. 2016 06; 71(6):1609-18.
Score: 0.120
-
Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics. 2013 Dec; 23(12):721-8.
Score: 0.103
-
Aquilante CL. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther. 2010 Mar; 8(3):359-72.
Score: 0.079
-
Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep; 10(9):1489-510.
Score: 0.077
-
Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 Sep; 84(3):326-31.
Score: 0.069
-
Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr. 2006 Aug 01; 42(4):441-9.
Score: 0.062
-
Zineh I, Pebanco GD, Aquilante CL, Gerhard T, Beitelshees AL, Beasley BN, Hartzema AG. Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs. Ann Pharmacother. 2006 Apr; 40(4):639-44.
Score: 0.060
-
Lin M, Aquilante C, Johnson JA, Wu R. Sequencing drug response with HapMap. Pharmacogenomics J. 2005; 5(3):149-56.
Score: 0.055
-
Zineh I, Gerhard T, Aquilante CL, Beitelshees AL, Beasley BN, Hartzema AG. Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J. 2004; 4(6):354-8.
Score: 0.052
-
Liko I, Corbin L, Tobin E, Aquilante CL, Lee YM. Implementation of a pharmacist-provided pharmacogenomics service in an executive health program. Am J Health Syst Pharm. 2021 06 07; 78(12):1094-1103.
Score: 0.043
-
Kile DA, MaWhinney S, Aquilante CL, Rower JE, Castillo-Mancilla JR, Anderson PL. A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1227-34.
Score: 0.023
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|